News articles about Endocyte (NASDAQ:ECYT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Endocyte earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.3533751566702 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Endocyte, Inc. (ECYT) VP Sells $117,084.24 in Stock (americanbankingnews.com)
- Why Endocyte, Inc. Stock Briefly Spiked Today (finance.yahoo.com)
- Zacks: Brokerages Expect Endocyte, Inc. (ECYT) to Announce -$0.16 EPS (americanbankingnews.com)
- Axovant Sciences Ltd., (NASDAQ: AXON), Endocyte, Inc., (NASDAQ: ECYT), Axon Enterprise, Inc., (NASDAQ: AAXN … – Stocks In The News (press release) (tradingnewsnow.com)
Endocyte (ECYT) opened at $4.81 on Tuesday. Endocyte has a twelve month low of $1.17 and a twelve month high of $6.55.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The firm had revenue of $0.03 million for the quarter. During the same quarter in the previous year, the business posted ($0.21) EPS. The business’s revenue was up .0% compared to the same quarter last year. research analysts forecast that Endocyte will post -1.24 earnings per share for the current year.
Several equities research analysts have weighed in on the stock. ValuEngine downgraded shares of Endocyte from a “hold” rating to a “sell” rating in a research note on Tuesday, November 14th. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a report on Thursday, November 9th. Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $2.00 to $7.00 in a report on Tuesday, October 3rd. Finally, Cowen reiterated a “hold” rating on shares of Endocyte in a report on Monday, October 2nd.
In other Endocyte news, VP Christopher P. Leamon sold 23,231 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.04, for a total value of $117,084.24. Following the transaction, the vice president now directly owns 150,579 shares in the company, valued at $758,918.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Philip S. Low bought 5,600 shares of the company’s stock in a transaction on Monday, November 13th. The stock was bought at an average price of $4.84 per share, for a total transaction of $27,104.00. Following the completion of the purchase, the insider now owns 283,005 shares of the company’s stock, valued at $1,369,744.20. The disclosure for this purchase can be found here. 14.86% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2017/12/05/endocyte-ecyt-receives-daily-media-sentiment-rating-of-0-11.html.
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.